This research project addresses an important problem faced by the chemical and drug industries? their requirement to evaluate the DNA damaging potential of ever larger numbers of new chemical entities in shorter periods of time. This situation presents opportunities for small businesses that are able to provide solutions to these challenges. The work proposed herein addresses industry's need for higher throughput toxicity assessment through the development of an automated in vitro chromosomal damage assay. Chromosome damage will be quantified by flow cytometric micronucleus measurements. Importantly, the methodology that will be developed over the course of this project not only represents a high volume genotoxicant screening system, but also one that can be configured to identify agents which protect against chromosomal damage. This project addresses a stated need of investigators working to develop the next generation of biological response modifiers (BRMs). BRMs that provide chemo- or radio-protection hold great promise in several important arenas, including cancer treatments which are typically dose-limited by normal tissue responses. The identification and development of BRMs have other important applications, and include enhanced protection of our troops during times of war, and also for civilian victims of chemical or radiological terrorist attacks. The planned Phase 1 and Phase 2 efforts have thus been designed to provide a rapid and efficient assay for detecting the genotoxicant, radioprotectant, or chemoprotectant potential of test chemicals. This screening assay will help chemical and drug companies allocate their resources to the most promising candidates, eliminating hazardous entities early in development. Furthermore, by aiding in the identification of next generation BRMs, cancer patients and armed forces will benefit from the availability of chemo- and radio-protectant drugs. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA117093-01A1
Application #
7107411
Study Section
Special Emphasis Panel (ZRG1-ONC-R (11))
Program Officer
Kim, Kelly Y
Project Start
2006-05-01
Project End
2006-12-31
Budget Start
2006-05-01
Budget End
2006-12-31
Support Year
1
Fiscal Year
2006
Total Cost
$133,336
Indirect Cost
Name
Litron Laboratories, Ltd.
Department
Type
DUNS #
085992055
City
Rochester
State
NY
Country
United States
Zip Code
14623
Bryce, Steven M; Avlasevich, Svetlana L; Bemis, Jeffrey C et al. (2008) Interlaboratory evaluation of a flow cytometric, high content in vitro micronucleus assay. Mutat Res 650:181-95
Bryce, Steven M; Bemis, Jeffrey C; Avlasevich, Svetlana L et al. (2007) In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity. Mutat Res 630:78-91